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ABSTRACT
Immune checkpoint inhibitors blocking the interaction between programmed death-1 (PD-1) and PD-1
ligand-1 (PD-L1) are revolutionizing the cancer immunotherapies with durable clinical responses.
Although high expression of PD-L1 in tumor tissues has been implicated to correlate with the better
response to the anti-PD-1 therapies, this association has been controversial. In this study, to characterize
immune microenvironment in tumors, we examined mRNA levels of immune-related genes and
characterized T cell repertoire in the tumors of 13 melanoma patients before and after nivolumab
treatment. We found that, in addition to the PD-L1 (p D 0.03), expression levels of PD-1 ligand-2 (PD-L2),
granzyme A (GZMA) and human leukocyte antigen-A (HLA-A) in the pre-treatment tumors were
signiﬁcantly higher (p D 0.04, p D 0.01 and p D 0.006, respectively) in responders (n D 5) than in non-
responders (n D 8). With nivolumab treatment, tumors in responders exhibited a substantial increase of
CD8, GZMA and perforin 1 (PRF1) expression levels as well as increased ratio of TBX21/GATA3, suggesting
dominancy of helper T cell type 1 (Th1) response to type 2 (Th2) response. T cell receptor b (TCR-b)
repertoire analysis revealed oligoclonal expansion of tumor-inﬁltrating T lymphocytes (TILs) in the tumor
tissues of the responders. Our ﬁndings suggest that melanoma harboring high PD-1 ligands (PD-L1 and
PD-L2), GZMA and HLA-A expression may respond preferentially to nivolumab treatment, which can
enhance Th1-skewed cellular immunity with oligoclonal expansion of TILs.
Abbreviations: CDR3, complementarity determining region 3; CTLs, cytotoxic T lymphocytes; HLA, human leucocyte
antigen; PD-1, programmed death-1; PD-L1, PD-1 ligand-1; PD-L2, PD-1 ligand-2; TCR, T cell receptor; TILs,
tumor-inﬁltrating lymphocytes
KEYWORDS
Metastatic melanoma;
nivolumab; oligoclonal T cell
expansion; PD-1;
T-cell receptor sequencing
Introduction
Immune checkpoint blockades, such as inhibitors of
programmed death 1 (PD-1) or PD-1 ligand-1 (PD-L1),
enhance antitumor immunity with the prominent clinical
responses in a wide range of cancers, including melanoma,
renal cell carcinoma, bladder cancer, hematologic malignancies,
and non-small cell lung cancer.1-4 For example, an anti-PD-1
antibody, nivolumab, has been recently approved in the United
States and Japan for the treatment of unresectable or metastatic
melanoma patients.5 Therapeutic anti-PD-1 antibodies inhibit
the interaction of PD-1 and its ligands, such as PD-L1 and
PD-1 ligand-2 (PD-L2), then effectively restore the antitumor
activity of tumor-inﬁltrating lymphocytes (TILs).2,4,6,7 Identiﬁ-
cation of a predictive biomarker(s) is critically important for
the precision medicine, which can select patients likely to have
clinical beneﬁt, reduce an unnecessary medical cost, and avoid
autoimmune adverse events. High expression levels of PD-L1
in tumor cells and inﬁltration of a high number of immune
cells have been suggested to correlate with clinical responses to
anti-PD-1 therapy,1,8,9 but several studies have shown clinical
beneﬁt of PD-1/PD-L1 antibodies even in patients lacking the
PD-L1 expression in cancer tissues.2,4,10
TILs play an essential role in orchestrating the host immune
response against cancer cells, and therefore characteristics of
TILs may represent the anti- (or pro-) tumor immune
response. A higher number of TILs in melanoma tissues were
correlated with prolonged patient survival and reduced risk of
metastasis,11 and persistent existence of clonal cytotoxic T
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lymphocytes (CTLs) has been documented in melanoma
tumors that responded well to adoptive T cell infusion ther-
apy.12,13 Therefore, comprehensive characterization of TILs
and immune microenvironment in tumor tissues is imperative
for better understanding of cancer immunotherapies. Recently,
we have established T cell receptor (TCR) repertoire analysis
which allowed us to characterize therapy-induced temporal
changes and clonal expansion of TILs using mRNAs isolated
from cancer tissues with next-generation sequencer.14-18
In this study, we analyzed mRNA expression levels of
immune-related genes in metastatic melanoma tumors of
patients who were treated with anti-PD-1 antibody (nivolu-
mab) and found high expression levels of PD-1 ligands (PD-L1
and PD-L2), GZMA, and HLA-A to be correlated with better
clinical response. Along with increase of CTLs and Th1-domi-
nant cellular immunity markers, we also detected oligoclonal
expansion of TILs in post-treatment tissues in the responders.
Results
Response-based classiﬁcation of melanoma patients
treated with nivolumab
We obtained pre- and post-treatment tumor tissues from 13
metastatic melanoma patients who were treated with nivolu-
mab. According to the RECIST criteria,19 2 cases were judged
as partial response (PR), 6 cases as stable disease (SD), and 5
cases as progressive disease (PD) (Table 1). The autoimmune-
like adverse events were observed in 3 cases; grade 1 hypothyr-
oiditis in 1 PR case, grade 2 psoriasiform dermatitis in 1 PR
case, and grade 4 myasthenia gravis with systemic myocarditis
and myositis in 1 SD case (Table 1). To examine effect of
immunological parameters on clinical outcome, we deﬁned
“responders” (n D 5) as patients who achieved PR or those
who revealed SD with progression-free survival (PFS) of greater
than a median period (233 d) of this cohort, and “non-respond-
ers” (n D 8) as patients who revealed PD or those who revealed
SD with PFS of less than the median (Table 1).
Expression of PD-1 ligands and response
to nivolumab treatment
High expression levels of PD-L1 in melanoma have been sug-
gested to be associated with better response to anti-PD-1 thera-
pies,1,8 but some results did not support this association.
Another PD-1 ligand, PD-L2 (B7-DC) is also known to sup-
press cytotoxic activity of T cells in tumor and thereby high
PD-L2 expression could be associated with the treatment
response.20 Hence, we ﬁrst examined PD-L1 and PD-L2 mRNA
levels in the pre-treatment tumor tissues and found that expres-
sion levels of both PD-L1 and PD-L2 were signiﬁcantly higher
in pre-treatment tumors of responders (n D 5) than those of
non-responders (n D 8) (p D 0.03 for PD-L1 and p D 0.04 for
PD-L2) (Fig. 1A and B); a strong correlation between the
expression levels of these two molecules was also observed
(Fig. S1A). Because responders had higher expression levels of
CD8 and PD-1 in tumors than non-responders (Fig. S1B), we
assumed that the responders had a higher number of pre-exist-
ing intratumoral CD8C T cells where the PD-1-PD-L1/2-
dependent inhibitory mechanism was likely to be dominant.
Other immune biomarkers to predict response
of nivolumab treatment
We then hypothesized that the pre-existing CD8C TILs in
responder tissues might have higher cytolytic activity, which
could be restored by nivolumab treatment. As expected, mRNA
level of granzyme A (GZMA), a cytolytic granule in CTLs, was
Table 1. Patient demographic data.
Patient Age Sex
Primary
lesion
Metastatic
lesions
History of
previous
treatments
BRAF
mutation
Pair of
samples
Response
(RECIST)
PFS
(d)
Response-
based
classiﬁcation
Adverse
events
M3 69 Female Sole In-transit metastases Operation, DAV-feron WT Pre and post PD 50 Non-responder None
M4 65 Male Sole Skin, lung Operation, DAV-feron,
DAC-tam
WT Pre and post PR 401 Responder Hypothyroidism
(Grade 1)
M5 69 Female Heel Skin Operation, DAV-feron Not tested Pre and post SD 190 Non-responder None
M6 80 Male Great toe In-transit metastases Operation, feron, DTIC WT Pre and post SD 443 Responder None
M7 78 Male Back In-transit metastases Operation, feron, DTIC WT Pre and post PR 428 Responder Psoriasiform
dermatitis
(Grade 2)
M8 65 Female Chest Lung, lymph
node, in-transit
metastases
Operation, feron, DTIC Not tested Pre PD 68 Non-responder None
M9 63 Female Face
(Eye lid)
Brain, pancreas,
skin, muscle
Operation, DTIC, g-knife WT Pre and post SD 276 Responder None
M10 85 Female Thumb Lung, skin Operation, DTIC, g-knife WT Pre SD 452 Responder None
M11 79 Male Sole Skin, inguinal
lymph nodes
Operation, DTIC WT Pre and post SD 130 Non-responder Myasthenia gravis,
myocarditis, and
myositis (Grade 4)
M13 66 Female Small toe Skin Operation, feron, DTIC WT Pre and post PD 72 Non-responder None
M14 75 Male Platae Stomach DTIC WT Pre and post PD 38 Non-responder None
M15 48 Male Great toe Skin Operation, feron WT Pre PD 12 Non-responder None
M17 82 Male Sole In-transit
metastases
Operation WT Pre and post SD 120 Non-responder None
Detailed clinical variables associated with prognosis in melanoma patients treated with nivolumab. DTIC, Dacarbazine; DAV-feron, dacarbazine C nimustine C vincristine C
interferon-b; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; WT, wild type.
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signiﬁcantly higher in pre-treatment tumors of responders than
those of non-responders (p D 0.01) (Fig. 1C). The expression
level of GZMA was signiﬁcantly correlated with those of PD-L1
(p D 0.001) and PD-L2 (p D 0.002) (Fig. S1C). In addition, it is
well known that HLA class I molecules must be expressed in
tumor cells to be recognized by CTLs. Hence, we examined
mRNA level ofHLA-A, one of the three major HLA class I mole-
cules, and found that it was signiﬁcantly higher in the pre-treat-
ment tumors in responders than those in non-responders (p D
0.006) (Fig. 1D). We further examined expression levels of addi-
tional immune-related genes including CD4, FOXP3, interleu-
kin-10 (IL-10), TBX21, and GATA3 as well as ratios of CD8/
FOXP3, CD8/CD4, and TBX21/GATA3 in the pre-treatment
tumors. Although there were no statistically signiﬁcant differen-
ces in expression levels of CD4, FOXP3, IL-10, TBX21 and
GATA3 between the two groups (Fig. S2), the CD8/FOXP3 and
CD8/CD4 ratios were signiﬁcantly higher in tumors in respond-
ers than those in non-responders (p D 0.04 and 0.02, respec-
tively), and the TBX21/GATA3 ratio showed higher tendency in
responders, compared with non-responders (pD 0.12) (Fig. 1E).
Based on statistical signiﬁcance of each gene, we selected three
possible predictive markers, PD-L1, GZMA, and HLA-A, and
applied to construction of a predictive scoring system (seeMate-
rials and Methods) for nivolumab treatment. The scoring system
using three possible biomarkers clearly distinguished the res-
ponders from non-responders (pD 0.0016) (Fig. 1F).
Nivolumab-driven immunological changes in the
tumor microenvironment
It is likely that blocking the PD-1 immune checkpoint can rein-
vigorate the pre-existing CTLs and enhance antitumor immune
responses. We therefore examined immunological changes
between pre- and post-treatment melanoma tissues and found
that nivolumab treatment increased the number of CD8 T cells
as indicated by the increase of CD8 mRNA in tumor tissues in
most of the cases (Fig. 2A). Particularly, in the cancer tissue of
patient M11, who was a non-responder but manifested severe
autoimmune adverse events21 displayed the most signiﬁcant
degree (4.1-folds) of CD8 increase (Fig. 2A, blue arrow). Fur-
thermore, we examined mRNA levels of GZMA and perforin 1
(PRF1), cytolytic activity markers of T cells, in tumor tissues.
Although changes of GZMA expression between the responder
and non-responder groups were not statistically signiﬁcant
(Fig. 2B), we observed signiﬁcant changes of PRF1 expression
levels between the two groups (p D 0.009) (Fig. 2C). These data
implying the enhancement of cytotoxic T cell activity might
also be supported by the Th1-dominant cellular immunity in
tumor tissues. We thereby investigated fold change of expres-
sion ratio of TBX21/GATA3 between before and after the nivo-
lumab treatment, which was likely to represent intratumoral
Th1/Th2 balance. The expression ratio of TBX21/GATA3 was
signiﬁcantly increased in responders than non-responders (p D
0.03) (Fig. 2D), suggesting that nivolumab treatment predomi-
nantly facilitated Th1-mediated adaptive cellular immune
response in melanoma tissues.
Oligoclonal T cell expansion in tumor tissues after
nivolumab treatment
To further characterize the inﬁltrated T cells in tumors, we
performed TCR repertoire analysis using our next-generation
sequencing method.14,18 Among 13 melanoma patients, 1
responder (M10) and 2 non-responders (M8 and M15) were
omitted for this analysis because their post-treatment tumors
were not available. After quantiﬁcation of individual TCR-b
Figure 1. Comparison of expression levels of multiple immune-related genes in pre-treatment tumors between responders and non-responders. (A–D) Expression levels
of PD-L1 (A), PD-L2 (B), GZMA (C), and HLA-A (D) genes in surgically resected pre-treatment tumors in responders and non-responders are shown. The y-axis indicates
expression level of each gene relative to that of GAPDH. (E) The expression ratios of CD8/FOXP3, CD8/CD4 and TBX21/GATA3 are presented. (F) Predictive scores for individ-
ual patients were calculated based on expression levels of PD-L1, GZMA, and HLA-A which were signiﬁcantly higher in the tumors of responders compared with those of
non-responders. Horizontal lines represent the means. The Mann–Whitney U test was used to examine statistical signiﬁcance.
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clonotypes based on unique V-D-J combinations with
complementarity-determining region 3 (CDR3) sequences, we
compared TCR-b repertoire in paired tumors of pre- and post-
nivolumab treatment (n D 10). Through cDNA sequencing of
TCR-b, we obtained total sequence reads of 1,040,729 §
708,603 (average § standard deviation) and unique CDR3
clonotypes of 32,880 § 30,631 in individual tissues (Table S1).
Interestingly, we found that TCR-b clonotypes with the read
frequency of >0.5% were drastically increased by nivolumab
treatment (Fig. 3A and B). For example, the proportion of
TCR-b clonotypes with the read frequency of > 0.5% tend to
be increased in the post-treatment tumor tissues of responders,
compared with those of non-responders; the proportions in 3
responders (M4, M6 and M7) were 41.4%, 61.9% and 87.9%,
respectively, while average and standard deviation of those in
non-responders were 29.1% § 28.1%. Although one remaining
responder, M9 did not show oligoclonal expansion of TILs by
the treatment, a tumor in this patient revealed the highest
expression levels of CD8, GZMA, and PRF1 in both pre- and
post-treatment tumors among all patients; this might imply a
possibility that polyclonal T cells with high cytolytic activity
were present in the tumors of this patient. To compare overall
changes in TCR-b repertoire between responders and non-
responders, we calculated the diversity index (DI) of TCR-b
repertoire to represent clonality of TILs and found a tendency
of the decrease of TCR-b DI in tumors of responders,
compared with those of non-responders (Fig. 3C).
Discussion
The PD-1/PD-L1 pathway functions as an immune evasion
mechanism in tumor, and anti-PD-1 therapies have shown
effective and durable antitumor responses in multiple types of
solid tumor, including melanoma.1-4 Overexpression of PD-L1
was suggested as a predictive biomarker for the response to the
anti-PD-1 therapies, but this association was controversial
probably due to the variability in the used antibodies and the
deﬁnition of positivity among the studies. Hence, at this point,
PD-L1 staining is considered to be insufﬁcient to select
appropriate patients for the therapies.22 Considering applica-
tion of this type of treatment to various cancer types as well as
its very expensive cost, it is crucially important to develop a
better predictive system to the anti-PD-1 therapies.
In this paper, we demonstrated signiﬁcant positive correla-
tions between expression levels of PD-L1 and PD-L2, and also
between those of PD-1 ligands (PD-L1 and PD-L2) and GZMA
in melanoma tissues. PD-L2 is one of the ligands for the PD-1
receptor and indicated to inhibit the effector function of T cells,
but its expression in tumors was reported to be less frequent (in
only 8 of 38 specimens examined),8 although PD-L1 and PD-L2
Figure 2. Nivolumab treatment-induced changes in the intratumoral expression of immune-related genes. Expression levels of CD8 (A), GZMA (B), PRF1 (C), and expres-
sion ratio of TBX21/GATA3 (D) in pre-treatment (pre) and post-treatment (post) tumors are presented. The y-axis indicates expression level of each gene relative to that of
GAPDH. Red circles and black squares indicate tumor samples from responders and non-responders, respectively. Blue arrows indicate a patient who manifested severe
adverse events (SAE). Asterisk indicates a patient whose expression of TBX21 in the tumor of post-treatment was undetectable. The Mann–Whitney U test was used to
examine statistical signiﬁcance.
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expression levels were well correlated in our samples. Another
immune escape mechanism of cancer cell is loss or decreased
expression of HLA class I molecules, which was frequently
observed in a range of human malignancies including mela-
noma.23-25 The pre-treatment tumors from responders exhibited
signiﬁcantly higher expression levels of PD-L1, GZMA, and
HLA-A than those from non-responders. When we made a
scoring system using these three markers, we were able to
separate two groups, responders and non-responders relatively
clearly. These results indicated that pre-existence of cytolytic T
cells and high expression of HLA class I molecules in tumors
might be good predictive markers for better clinical response to
nivolumab treatment. Since, this kind of approach often causes
over-ﬁtting, further investigation to examine the expression lev-
els of PD-L1, GZMA and HLA-A in pre-treatment tumors of an
independent cohort of melanoma patients treated with nivolu-
mab will be deﬁnitely needed. In addition, pre-treatment tumors
from responders showed a tendency of increased expression
levels of CD8 and PD-1, which was consistent with previous
results showing that the density of CD8 cells and PD-1C cells in
melanoma of pre-treatment biopsy samples was signiﬁcantly
higher in responders than non-responders.9 Therefore, statistical
signiﬁcance may be attained by further analysis of more patients
and consideration of additional immunologic factors.
Secondly, we examined nivolumab-induced changes in the
immune microenvironment by assessing expression levels of
immune-related molecules and clonality of tumor-inﬁltrated T
cells. Our results demonstrated that all of four paired tumor
tissues from responders showed substantial increase of
cytotoxic T cells reﬂected by the increase of CD8, GZMA, and
PRF1, compared with those from non-responders; particularly
signiﬁcant increase of PRF1 indicates activation of CD8 T cells.
Although both granzyme and perforin are essential for cytolytic
activity of CTLs, it was reported that expression of perforin was
suppressed in the PD-1C T cells.26,27 Therefore, our results
implied that the high level of perforin expression could be
restored by blocking PD-1 pathway with nivolumab treatment,
which subsequently conferred higher cytolytic activity of CTLs
in the tumors of responders. Another important ﬁnding was
signiﬁcant elevation of Th1 cellular immunity, as indicated by
increased TBX21/GATA3 expression ratio, in the nivolumab-
treated tumors of responders. These results implied that nivolu-
mab treatment could increase Th1 cell-mediated adaptive cellu-
lar immunity and cytolytic activity of CTLs, leading to effective
generation/expansion of antitumor CTLs in tumors.
Since our results from gene expression analysis indicated
that nivolumab treatment restored the CTL activity in tumor,
we attempted to characterize T cell repertoire in tumors
through TCR deep sequencing analysis. Consequently, we
found that nivolumab treatment induced oligoclonal enrich-
ment of certain TCR-b clonotypes in the tumor tissues of
responders, which was consistent with a previous report of
anti-PD-1 (pembrolizumab)-treated melanoma showing that
tumors of better responders displayed signiﬁcant clonal
expansion of TCR-b by the treatment.9
Immune checkpoint inhibitors have revolutionized the can-
cer immunotherapies, but the tumor–host immune interaction
is not yet completely elucidated in the molecular level. Integra-
tion of whole exome/genome sequencing, characterization of
the immune microenvironment through transcriptome analysis
and TCR sequencing will confer better understating in the
mechanisms of action for cancer immunotherapies.28 Indeed,
Figure 3. Nivolumab treatment-induced changes of TCR-b repertoires in tumors. Pie charts illustrate distribution of unique CDR3 sequences of TCR-b, detected in paired
tumor samples of pre- and post-treatment, from responders (n D 4) (A) or non-responders (n D 6) (B). As each pie chart was separately colored according to CDR3s fre-
quency ranks, the same color between pie charts does not represent an identical CDR3 sequence. Gray color zone indicates combined portion of all clonotypes with the
frequencies of less than 0.5%. (C) Fold changes in the diversity index (DI) of TCR-b in tumors are shown according to the patient’s response to nivolumab treatment. Hori-
zontal lines represent the means, and the Mann–Whitney U test was used to examine statistical signiﬁcance.
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results from whole-exome sequencing of non-small cell lung
cancers treated with pembrolizumab revealed that higher num-
ber of non-synonymous mutations and predicted neoantigens
(generated from non-synonymous mutation) were associated
with better clinical outcome.29 This ﬁnding implicated that
presence of abundant and immunogenic tumor antigens might
be another indicator for effective anti-PD-1 therapy. Future
studies aiming identiﬁcation of such potent tumor antigens and
corresponding TCR sequences will contribute to development
of genetically engineered T cells for adoptive T cell therapy.
In summary, we have indicated that not only expression lev-
els of PD-1 ligands but also those of GZMA and HLA-A in mel-
anoma tissues might predict nivolumab treatment response and
that nivolumab treatment enhanced Th1-skewed cellular immu-
nity in tumor and induced oligoclonal expansion of TILs with
cytolytic activity. The results presented here could provide new
insights in the development of novel cancer immunotherapies.
Materials and methods
Patient samples
A total of 13 metastatic melanoma patients (M3, M4, M6, M7,
M8, M9, M10, M11, M13, M14, M15, and M17), who had
received dacarbazine-based chemotherapy and/or other
immunotherapy (interferon-b), were enrolled in Kumamoto
University Hospital, Shinshu University Hospital, Tsukuba
University Hospital, Nagoya University Hospital, Nagoya City
University Hospital, and Kyoto Prefectural University of Medi-
cine Hospital. Detailed clinical information of melanoma
patients is summarized in Table 1. Metastatic skin melanoma
tissues of pre- and post-nivolumab treatment, in which pre-
and post-treatment tumors were surgically resected from differ-
ent skin lesions, were collected according to a study protocol
approved by Institutional Review Board of each institution.
Informed consents were collected from all the patients. All
samples were transferred to the University of Chicago, and sub-
sequently TCR-b repertoire was analyzed under the University
of Chicago IRB protocol 13-0797. For TCR repertoire analysis
using paired pre- and post-treatment tumors, 1 responder
(M10) and 2 non-responders (M8 and M15) among all 13
patients were excluded for this analysis because their post-treat-
ment tumors were not available.
Gene expression analysis
To examine expression levels of immune-related genes, total
RNA was extracted using RNeasy mini kit (Qiagen) from fro-
zen tissues of tumors. We synthesized cDNA with 50 rapid
ampliﬁcation of cDNA end (50-RACE) adapter using SMART
cDNA library kit (Clontech). Gene expression analysis was per-
formed on the tumor cDNA samples using TaqMan gene
expression assays (Thermo Fisher Scientiﬁc) according to the
manufacturer’s instructions. A housekeeping gene, GAPDH
(assay Hs02758991_g1) was used for data normalization. For
the predictive score (PS), we used expression levels of three
genes (PD-L1, GZMA, and HLA-A) that were signiﬁcantly
higher in the tumors of responders and calculated the PS in
each tumor sample using the following formulation: PS D R
(PD-L1) C R (GZMA) C R (HLA-A), where the R is deﬁned as
Log2 (expression level in each case/average of expression levels
in all cases).
TCR-b sequencing
The libraries for TCR-b sequencing were prepared using previ-
ously described methods.14,18 Brieﬂy, cDNA with 50-RACE
adapter was synthesized as described above. The TCR-b chains
were ampliﬁed using a reverse primer speciﬁc to the constant
region and a forward primer for the SMART adapter. Illumina
sequence adapters with barcode sequence were then added
using the Nextera XT Index kit (Illumina). Sequencing was per-
formed by 300-bp paired-end reads on the Illumina MiSeq plat-
form, using MiSeq Reagent v3 600-cycle kit (Illumina).
TCR-b repertoire analysis
TCR-b repertoire analysis was performed using Tcrip soft-
ware.14 Brieﬂy, sequencing reads were mapped to the human
TCR-b reference sequences using Bowtie2 aligner, and then
decomposed to the V-D-J components of the CDR3s.14 The
inverse Simpson’s DI value was calculated to quantify the
clonality of the TCR-b repertoires according to DI DhPK
iD 1 ni.ni¡ 1/
N N ¡ 1ð Þ
i¡ 1
,30 where N is the total number of
sequences, ni is the number of sequences belonging to the ith
clonotype, and K is the total number of clonotypes. To present
TCR-b repertoire of each sample, we used the Excel program
(Microsoft) to generate bar graphs and pie charts.
Statistical analysis
Gene expression level and TCR-b DI were compared
between patient groups using the Mann–Whitney U test
(two-tailed). Statistical analysis was carried out using Prism
6 software (GraphPad). p < 0.05 was considered statistically
signiﬁcant.
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